HealthTree Podcast for Multiple Myeloma HealthTree Podcast for MM
-
- Health & Fitness
-
HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.
-
Using all the Myeloma Tools in the Toolbox with Clifton Mo, MD, Dana Farber Cancer Institute
Dr. Clifton Mo of Dana Farber Cancer Institue shares a multitude of tools available in the myeloma toolbox. This includes all of the "standard of care" drugs that we are familiar with such as immunomodulators, proteasome inhibitors, steroids, monoclonal antibodies as well as tools in development.
He reviews triplet combo treatment options at first relapse and his preference to use Kyprolis in the mix, especially when given a more aggressive myeloma.
Dr. Mo explains how antibody drug conjugates (ADCs) work and how the first ADC, BLENREP, may be making a comeback. He shares how dexamethasone can be reduced or stopped under certain conditions. He explains BCL-2 inhibitors like venetoclax and how they are making their way through clinical trials.
Dr. Mo describes celmods and how they work and are a promising new class of drugs. He also described how an XPO1 inhibitor called selinexor is being used both with the celmods and alone as an agent that works well for higher risk myeloma.
This shows myeloma patients how fortunate we are to have these tools available and speaks to the importance of having a myeloma specialist on your team who can help you make treatment decisions. This can be done alone or in partnership with your local oncologist. There is data that shows that having a specialist on year team leads to longer life. -
Alfred Garfall, MD and Bea Razzo, MD on Bispecific Antibodies in Multiple Myeloma
Learn how bispecific antibodies are being used in multiple myeloma care and how physicians are helping patients manage side effects using new approaches like fixed-duration therapy.
-
The 2024 Myeloma Landscape with Robert Orlowski, MD, PhD, MD Anderson
The year 2024 brings new promise in multiple myeloma with a wide variety of treatment options avaiable for both newly diagnosed and relapsed/refractory patients. Learn about the progress being made and the very latest in determining risk at diagnosis, strategies for smoldering myeloma patients, optimal treatments for newly diagnosed patients, things to consider at first relapse and beyond. Dr. Robert Orlowski will review advances in CAR T therapies, bispecific antibodies, targeted therapies and combination approaches and clinical trials to watch as the research continues advancing at a rapid pace in myeloma.
Thanks to our episode sponsor, GSK. -
Today's CAR T Options in Multiple Myeloma Care with Luciano Costa, MD, UAB
CAR T therapy is a highly effective treatment for myeloma patients, even in highly relapsed multiple myeloma. In today's show we will hear from Luciano Costa, MD of the University of Burmingham who will do a deep dive into CAR T therapy in multiple myeloma to discuss how CAR T availability is improving, how CAR T is being tested in earlier lines of therapy, side effects to consider, new CAR T targets, combo CAR Ts, maintenance therapy post-CAR T, open CAR T clinical trials and various new forms CAR T variants like NK CAR Ts. Join us for this important show on one of the most impressive therapies ever developed in myeloma!
Thanks to our episode sponsor,
Menarini Silicon Biosystems -
Multiple myeloma mid-year progress with Dr. Paul Richardson of Dana Farber
Dr. Paul Richardson of the Dana Farber Cancer Institute shares a mid-year myeloma review of ASCO, EHA and upcoming International Myeloma Society findings of the fast-moving research being performed in myeloma. Updates will include the expanding world of bispecific antibodies that include one FDA-approved drug and anticipated approvals for two new bispecific antibodies. He will also discuss exciting results from CAR T cinical trials, CAR T newcomers, sequencing preferences, BCMA targeted therapies, new therapy targets in myeloma, MRD advances, blood-based testing, clinical trials end points and more.
Thanks to our episode sponsor, Karyopharm. -
Stem Cell Transplant Advances and Use in the Age of Immunotherapy
Stem cell transplant remains a useful and widely used treatment for multiple myeloma. John DiPersio, MD, PhD of the Siteman Cancer Center at Washington University joins HealthTree Podcast for Multiple Myeloma to discuss stem cell transplant in myeloma, a new and better way to collect stem cells as part of the process and the utility of stem cell transplant in the age of immunotherapies.
Thanks to our episode sponsor, GSK
Customer Reviews
Bringing awareness and knowledge on MM
Well structure conversations with top specialists in the field of MM. A must subscription for patients, caregivers and professionals.
one more step towards a cure for myeloma
This is a great service that you are providing to myeloma patients and care givers. Thank you and keep up the great work on your journey to find a cure.